Clinical Trials on Unresectable Non-Small Cell Lung Carcinoma

Total 8139 results

National Cancer Institute (NCI)

Completed

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States, Mexico, Bolivia, Peru, Venezuela
National Cancer Institute (NCI)
University of Chicago; City of Hope Medical Center; University of Southern California and other collaborators

Completed

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Non Small Cell Lung Carcinoma

United States
Eli Lilly and Company

Completed

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States
University Hospital, Bordeaux

Completed

Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers (PULMOTEP)

Lung Cancer | Non-small-cell Lung Carcinoma

France
Genentech, Inc.

Completed

A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small-cell Lung Carcinoma

United States
Bristol-Myers Squibb

Terminated

A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

Non Small Cell Lung Cancer

United States
AstraZeneca

Completed

ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

Australia
University Hospital, Grenoble

Completed

Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma (METABO-ICI)

Non Small Cell Lung Cancer

France
Eli Lilly and Company

Completed

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States, Canada
Tony Bekaii-Saab
Roche Pharma AG

Completed

A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients

Lung Cancer | Non-Small-Cell Lung Carcinoma

United States
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

PET Imaging in Potentially Surgically Resectable Non-small Cell Lung Cancers (ELPET)

Non-small-cell Lung Carcinoma

Canada
National Cancer Institute (NCI)

Completed

BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States
GenoSaber

Unknown

The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring

Non-small-cell Lung Carcinoma
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Stage IV Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IIIB | EGFR Negative Non-Small Cell Lung Cancer

United States
M.D. Anderson Cancer Center

Active, not recruiting

Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Malignant Solid Neoplasm | Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Recurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca

Recruiting

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

NSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

United States
Virginia Commonwealth University
National Cancer Institute (NCI)

Withdrawn

Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Recurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
University Medical Centre Maribor
Institute of Oncology Ljubljana; The University Clinic of Pulmonary and Allergic...

Recruiting

Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer (PRIMM)

Carcinoma, Non-Small-Cell Lung | Non Small Cell Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma

Slovenia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

Recurrent Lung Non-Small Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States, Canada
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Megan Daly, MD
National Cancer Institute (NCI); Genentech, Inc.

Terminated

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
University of Washington
National Cancer Institute (NCI); Celgene Corporation

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Biocad

Unknown

Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) (DOMINUS)

Non Small Cell Lung Cancer Stage IIIB | Non-Small Cell Carcinoma of Lung, TNM Stage 4

Russian Federation, Belarus
Washington University School of Medicine
BioMarin Pharmaceutical

Withdrawn

Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors

Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Solid Tumors | Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

Small Cell Lung Cancer | Solid Tumor | Non-small Cell Lung Cancer
National Cancer Institute (NCI)

Completed

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
Samsung Medical Center

Not yet recruiting

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | EGFR T790M

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Carcinoma

United States
European Organisation for Research and Treatment...

Unknown

Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo (EVIDENCE)

Non-small Cell Lung Carcinoma

Italy, United Kingdom
Trans Tasman Radiation Oncology Group
Cancer Council Queensland; Victorian Cancer Council

Completed

Chemoradiotherapy in Patients With Localised Lung Cancer

Non Small Cell Lung Carcinoma

Australia
Addario Lung Cancer Medical Institute

Terminated

Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network (CASTLE)

Small Cell Lung Carcinoma | Non-small Cell Lung Cancer Metastatic
Alliance Foundation Trials, LLC.
Bristol-Myers Squibb; Celgene Corporation

Terminated

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

Nonsmall Cell Lung Cancer | Non Small Cell Lung Cancer Recurrent | Non-Small Cell Carcinoma of Lung, TNM Stage 4 | Non-Small-Cell Lung Cancer Metastatic

United States
National Cancer Institute (NCI)

Active, not recruiting

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

EGFR-Mutated Non-Small-Cell Lung Carcinoma | Small Cell/Neuroendocrine

United States
University Health Network, Toronto

Recruiting

Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Non-small Cell Carcinoma

Canada
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Lung Cancer, Nonsmall Cell

United States
Roswell Park Cancer Institute

Completed

Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Emory University
Washington University Siteman Cancer Center

Active, not recruiting

An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
Peking University
Merck Sharp & Dohme LLC; Cancer Institute and Hospital, Chinese Academy of... and other collaborators

Recruiting

Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

Stage IIIA Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer | Stage IIIB(N2) Non-small Cell Lung Cancer

China
Washington University School of Medicine

Active, not recruiting

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IIB Non-Small Cell Lung Cancer | Stage IIIC Non-Small Cell Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Nestlé Health Science

Withdrawn

Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢA

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

Advanced Squamous Non-Small Cell Lung Carcinoma

China
University of Illinois at Chicago

Recruiting

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC) (LUNG-IST-127)

Metastatic Squamous Non-Small Cell Lung Carcinoma

United States
AstraZeneca

Active, not recruiting

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)

Non Small Cell Lung Carcinoma NSCLC

Denmark, United Kingdom, United States, Poland, Brazil, India, Japan, Mexico, Peru, Russian Federation, Turkey, China, Malaysia, Hong Kong, Korea, Republic of, Chile, Israel, Ukraine, Portugal, Greece, Bulgaria, Philippines, Sweden, A... and more
AstraZeneca

Active, not recruiting

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Non Small Cell Lung Carcinoma NSCLC

Poland, Taiwan, Thailand, Vietnam, United States, Korea, Republic of, Hungary, Russian Federation, Turkey, China, Australia, Netherlands
AstraZeneca

Active, not recruiting

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)

Non-Small-Cell Lung Carcinoma NSCLC

United States, Belgium, Spain, Canada, Taiwan, Thailand, Vietnam, France, Germany, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, Netherlands, Australia, Switzerland

Clinical Trials on Unresectable Non-Small Cell Lung Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations